KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesBeginning Cash BalanceCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Other financing activities: 2013-2024

Historic Other financing activities for Esperion Therapeutics (ESPR) over the last 7 years, with Dec 2024 value amounting to $29,000.

  • Esperion Therapeutics' Other financing activities was N/A to $7.5 million in Q1 2025 from the same period last year, while for Mar 2025 it was $7.5 million, marking a year-over-year change of. This contributed to the annual value of $29,000 for FY2024, which is 38.10% up from last year.
  • According to the latest figures from FY2024, Esperion Therapeutics' Other financing activities is $29,000, which was up 38.10% from $21,000 recorded in FY2023.
  • In the past 5 years, Esperion Therapeutics' Other financing activities registered a high of $8.4 million during FY2020, and its lowest value of -$219,000 during FY2022.
  • Over the past 3 years, Esperion Therapeutics' median Other financing activities value was $21,000 (recorded in 2023), while the average stood at -$56,333.
  • As far as peak fluctuations go, Esperion Therapeutics' Other financing activities tumbled by 149.77% in 2022, and later spiked by 109.59% in 2023.
  • Over the past 5 years, Esperion Therapeutics' Other financing activities (Yearly) stood at $8.4 million in 2020, then tumbled by 94.77% to $440,000 in 2021, then tumbled by 149.77% to -$219,000 in 2022, then surged by 109.59% to $21,000 in 2023, then surged by 38.10% to $29,000 in 2024.